Over-expression of ALK fusion protein increased PD-L1 expression, while anti-PD-1 antibody (immunotherapy) was effective in both crizotinib sensitive and resistant NSCLC cells (32). This evidence concerns the gene ALK and non-small cell lung carcinoma.